restricted to secondary and tertiary care centres. Identification of MSU crystals in a primary care setting is usually not feasible as it requires both expertise in joint puncture and expensive equipment those are not readily accessible. In patients suffering from acute arthritis and in whom synovial fluid analysis is difficult, the diagnosis of gout flare should be based on certain suggestive clinical features and the serum uric acid level in a primary care setting. [5] The 2015 American College of Rheumatology-European League Against Rheumatism (ACR-EULAR gout classification criteria [6, 7] is a standardised and highly specific approach to identify relatively homogeneous group of individuals who have the clinical entity of gout in a primary care setup. The entry criterion requires the occurrence of at least 1 (one) episode of peripheral joint or bursal swelling, pain or tenderness. The domains of this criterion include clinical (pattern of joint/bursa involvement, characteristics and time course of symptomatic episodes), laboratory (serum urate and MSU-negative synovial fluid aspirate) and imaging (double contour sign on ultrasound or urate on dual-energy computed tomography and radiographic gout-related erosion).
PubMed search revealed total 17,736 studies on gout, of which only five used the Gout Assessment Questionnaire (GAQ) and only three studies [8] [9] [10] used Homoeopathy. However, no study result could be elucidated with GAQ2 , Measure Yourself Medical Outcome Profile v2.0 (MYMOP2) and Homoeopathy. As per AYUSH Research Portal, total 21 clinical research works on gout under AYUSH system were carried out, but of those, only one was with Homoeopathy. It was a qualitative study in which ten individuals presented themselves within 5 days of the onset of acute gout and participated in a 15-day study period. Serum uric acid levels were tested on day 1 and day 6 to assess hyperuricaemia. Treatment effect was evaluated on days 1, 3 and 6 based on day subjective. This single-arm, open-label study generated some promising results in favour of Homoeopathy in treatment of acute gout within 6 days, but due to its obvious methodological shortcomings, the results can be considered as preliminary only. [11] Thus, literature on homoeopathic medicines in the treatment of gout with improvement in the quality of life remains insufficient. As the existing evidences remain miniscule, at the very first attempt, we aimed to generate some preliminary data about any possible effects of Homoeopathy in gout in pre-post comparison design, to be subjected to explanatory robust trials in future.
Methods

Setting and design
A prospective, single-arm, non-randomised, open-label, observational trial was conducted from November 2017 to April 2018 on 32 adult individuals suffering from gout (as per the ACR-EULAR gout classification criteria) at the Outpatient Department of The Calcutta Homoeopathic Medical College and Hospital (CHMC and H), Kolkata. The proposed plan of work adhered to the ethical guidelines of the Declaration of Helsinki [12] and was approved by the Ethical Committee of the institution (CHMCH/IEC/13/2018, dated 05 January 2018) retrospectively. The trial could not, however, be registered with the Clinical Trials Registry of India due to a retrospective approval of the Ethical Committee. Each patient was provided with a patient information sheet in local vernacular Bengali language detailing the objectives, methods, risks and benefits of participating and confidentiality issues. Before enrolment, written informed consent was taken from the patients.
Inclusion and exclusion criteria
Individuals of either of the sexes of age 18 years and above, who had scored 8 or more in the 2015 ACR-EULAR gout classification criteria, having no unstable psychiatric illness or other systemic disease and who have not used any medication in the past 1 month were enrolled. Patients who did not give consent were excluded. Case taking was done for each patient in accordance with the standardized homoeopathic principles. Cases with manifestation of causes for secondary gout were ruled out. All the cases were diagnosed only on the basis of serum uric acid and clinical assessment. Radiological or synovial fluid examination was not done, as those were not available at the institution. Patients with score more than or equal to 8 were included, without the score of the said two examinations.
Outcome assessment
• P r i m a r y o u t c o m e -S e r u m u r i c a c i d l e v e l (baseline vs. 3 months) • Secondary outcomes -GAQ2 [13] (baseline vs. 3 months) and MYMOP2 [14] (baseline, every month and up to 3 months).
All outcomes were recorded in pre-designed follow-up forms; influence of gout on health-related quality of life of patients was assessed through GAQ2 measured at baseline and at the 3 rd month. GAQ2 is a disease-specific patient-reported outcome measure with 24 items, consisting of 5 different subscales: gout concern overall, gout medication side effects, well-being during attack, unmet gout treatment needs and gout concern during attack. Each item of the GAQ2 is rated 'strongly agree' to 'strongly disagree', 'all of the time' to 'none of the time' or 'not a bit' to 'extremely' on a 5-point Likert scale. A higher score denotes a greater impact of disease. It has five domains: gout concern overall, gout medication side effects, well-being during attack, unmet gout treatment needs and gout concern during attack.
Patients' responses were assessed through MYMOP2 initial and follow-up forms, measured and analysed at baseline, after the 1 st , 2 nd and 3 rd months. The most troublesome symptom of gout in each case was recorded as Symptom 1, the intensity of which was marked by a patient on a 7-point scale (from 0 to 6, 0 = as good as it can be and 6 = as bad as it can be); simultaneously, activity, well-being of the individual and other associated symptom in each case was recorded as Symptom 2 and the intensity was scored. Patients presented with pain in heels, pain in knee, pain in toes and swelling of toe with pain as Symptom 1, and as Symptom 2, the participants presented with varied ailments like gastrointestinal complaints such as bleeding per rectum, constipation, bloated abdomen and mucoid stool; urinary complaints such as scanty urine, burning in micturition and offensive urine and sleeplessness.
Intervention and follow-up
All patients were given appropriate individualised homoeopathic medicines based on homoeopathic principles. Patients were advised to take care of their lifestyle by altering the diet and regimen. Cases were repertorized if required. Repetition was done depending on the individual requirement of the cases. Each patient enrolled was intervened for a period of 3 months, and follow-up was conducted at least once a month or earlier, as required by the patient.
Statistical analysis
Both descriptive and inferential statistics were used. Intention-to-treat sample was subjected to statistical analysis. Missing values were replaced by last value carried forward method. Student's t-test and one-way repeated measures ANOVA were used keeping P < 0.05 two-tailed as statistically significant. Statistical Package for the Social Sciences, version 20.0 (IBM Corp., IBM SPSS Statistics for Windows, Armonk, NY: USA) was used for analysis.
Results
Study flow
A total of 55 patients were preliminarily screened on the basis of entry criterion of occurrence of at least one episode of peripheral joint or bursal swelling, pain or tenderness and serum uric acid level. Of which, 45 were assessed for eligibility. No patient underwent radiological examination or synovial fluid examination, as they were not available at the institution. The ACR-EULAR gout score was <8 in 9 patients and 4 did not give consent. Hence, only 32 patients could be enrolled in the study after screening them according to the inclusion and exclusion criteria [ Figure 1 ].
Baseline features
The maximum number of patients belonged to the age group of 31-40 years (n = 11; 34.4%) and 41-50 years (n = 11; 34.4%), followed by 51-60 years (n = 7; 21.9%) [ Table 1 ]. Male patients were the majority (n = 20; 62.5%). Further, 65.6% (n = 21) of the patients had mixed type of diet, 9 patients (28.1%) had regular smoking habit, 1 patient had a habit of regular consumption of alcohol and 11 patients (34.4%) occasionally took alcohol. Dietary habit of intake of red meat regularly was presented in 9.4% (n = 3) patients, whereas 37.5% (n = 12) of the patients occasionally consumed red meat and 21 (65.6%) patients occasionally consumed soft drinks [ Table 2 ]. The mean ACR-EULAR gout score was 8.2, with 62.5% (n = 20) having a score of 8 and 34.4% (n = 11) with score of 11. None of the patients were with score 12 and above [ Table 2 ].
The other comorbid conditions recorded in Symptom 2 of MYMOP2 were-gastrointestinal complaints (6 patients), haemorrhoids with bleeding per rectum (2 patients), constipation (1 patient), mucoid stool (1 patient), cough, sleeplessness in 2 patients, urinary complaints in 4 patients, scanty menses with engorgement of breast before menses in one patient and warm sensation, wet sensation, itching, burning sensation on legs, chronic intertrigo and otorrhoea in one patient each.
Symptom profile
Among the total 32 patients enrolled for the study, 2 patients presented with classical acute gout, i.e. sudden development of a painful, swollen, warm metatarsophalangeal joint, whereas 7 patients had involvement of monoarticular joint and rest of the 23 patients had polyarticular joint involvement. Table 3 ]. The pre-medication mean score of concern of gout medication side effects reduced from 4.7 to 1.6 after 3 months of treatment, whereas the mean score of concern of well-being during attack reduced from 19.3 to 9.5 and after medication gout concern during attack reduced from 8.1 to 3.9 [ Table 3 ]. The mean pain intensity score of MYMOP2 (Symptom 1) improved from 5.2 (baseline) to 4.3 (at the 1 st month), 3.8 (at the 2 nd month) and finally 3 (at the 3 rd month). The mean activity score improved from 4.8 (baseline) to 3.9 (at the 1 st month), 3.5 (at the 2 nd month) and finally 2.7 (at the 3 rd month) after medication. The mean well-being score of the patients with gout also improved from 5.1 (baseline) to 4.1 (at the 1 st month), 3.5 (at the 2 nd month) and finally 2.5 (at the 3 rd month). A significant improvement in the mean intensity score of associated symptom in each case (recorded as Symptom 2) was changed from 3.9 at baseline to 1.6 after the 3 rd month [ Table 4 ].
Homoeopathic medicines used
As per the totality of symptoms, at the baseline, Benzoicum acidum was prescribed in 8 patients (25%) and Lachesis mutus, Lycopodium clavatum, Pulsatilla nigricans and Rhus toxicodendron were prescribed in 3 patients (9.4%) each. In the subsequent prescriptions also, Benzoicum acidum was the most frequently used medicine, followed by Colchicum autumnale. The indicated medicines were prescribed in different potencies as per the susceptibility of each individual patient and guidelines of the Organon of Medicine. Medicines were changed as per the demand of each case, when there was no such marked improvement or totality of symptoms changed. Placebo was prescribed as long as improvement continued. Among the 32 patients, no change of medicine was required for 18 patients, though repetition or prescription of higher potencies was prescribed when cases came to a standstill and the same potency was not enough to cure the case. The lists of prescribed medicines and the indications of the most frequently prescribed remedies are given in Tables 5 and 6 , respectively.
dIscussIon
Compared to baseline, serum uric acid, GAQ2 and MYMOP2 scores of participants reduced significantly over three months. As per the totality of symptoms, twenty different homoeopathic medicines were used, Benzoicum acidum being the most common.
It was observed that many associated symptoms of the patient, such as acidity, sleeplessness, bleeding per rectum, constipation, cough and itching (MYMOP2, Symptom 2), improved, suggesting Homoeopathy as a holistic care therapeutic method. This study elicited the potential effect of individualised homoeopathic medicines in not only reducing the serum uric acid but also improvement in activity and well-being of patients with gout, without any substantial medicinal adverse effects. The methodological strengths of the study were its prospective design, use of validated questionnaires, such as GAQ2 and MYMOP2, treatment by qualified and experienced homoeopathic physicians schooled in and practicing classical Homoeopathy in dealing with a challenging condition like gout -a single, simple medicine in minimum dose based on totality of symptoms in each individual case. No such published homoeopathic studies on gout could be identified to compare the findings of MYMOP2. The single published study [8] was an open-label, single-arm trial involving only ten individuals who presented within 5 days of the onset of acute gout. Three outcome measures were used -serum uric acid level, joint improvement score and Ritchie's score of joint swelling and joint tenderness -all assessed on days 1, 3 and .001 ψψψψ *t 31 =5.400, P<0.001, **t 31 =6.466, P<0.001, ***t 31 =8.752, P<0.001 (pairwise comparison using paired t-test), ****Wilks' λ=0.278, F 3 , 29=25.112, partial η 2 =0.722 (One-way repeated measures ANOVA), # t 31 =4.543, P<0.001, ## t 31 =6.225, P<0.001, ### t 31 =7.629, P<0.001 (pairwise comparison using paired t-test), #### Wilks' λ=0.346, F 3 , 29=18.291, partial η 2 =0.654 (One-way repeated measures ANOVA), ¥ t 31 =5.593, P<0.001, ¥¥ t 31 =7.314, P<0.001, ¥¥¥ t 31 =9.655, P<0.001 (pairwise comparison using paired t-test), ¥¥¥¥ Wilks' λ=0.252, F 3 , 29=27.641, partial η 2 =0.748 (One-way repeated measures ANOVA), ψ t 31 =6.241, P<0.001, ψψ t 31 =9.644, P<0.001, ψψψ t 31 =10.114, P<0.001 (pairwise comparison using paired t-test), ψψψψ Wilks' λ=0.201, F 3 , 29=38.544, partial η 2 =0.799 (One-way repeated measures ANOVA). MYMOP2: Measure Yourself Medical Outcome Profile v2.0, SD: Standard deviation, CI: Confidence interval 6. All the acute symptoms of gout were found to be resolved within a span of 6 days only. Among the used medicines, Benzoic acid, Causticum, Rhus toxicodendron, Ledum palustre, Colchicum autumnale and Calcarea carbonica were common. The findings were preliminary only and further studies were warranted. The period of study was, however less to evaluate the effect of treatment in reducing the progress of the disease and in preventing acute attacks. In the absence of control arm, there is always chance of overestimation of treatment effect sizes. In comparison, our study was better than this in terms of number of patients, use of validated questionnaires as secondary outcomes, longer duration of follow-ups and comparatively rigorous statistical analysis. Adequately powered randomised controlled trials are warranted to arrive at a definite conclusion regarding the efficacy of homoeopathic medicines in gout.
conclusIon Homoeopathic management has adequate potential in not only alleviating the serum uric acid in gout but also a significant role in improving the well-being, activity and quality of life of patients with gout, without any adverse effects. This prospective observational trial, though preliminary, revealed a positive treatment effect of homoeopathic medicines in gout. The study findings need to be interpreted with caution and further be experimented in randomised placebo-controlled design with enhanced methodological rigor and longer follow-up. 
Un essai d'observation prospectif pour évaluer l'effet des médicaments homéopathiques chez les patients souffrant de goutte
Contexte : La goutte est une arthrite inflammatoire associée à l'hyperuricémie et au dépôt de cristaux d'urate monosodique inter-articulaire (MSU), entraînant de la douleur, une limitation de l'activité, un handicap et ayant un impact sur la qualité de vie du patient. Objectif : Examiner les effets des médicaments homéopathiques personnalisés sur le taux d'acide urique sérique et la qualité de vie chez les patients souffrant de goutte. Méthodes : Un essai d'observation prospectif ouvert non randomisé sur groupe unique a été mené sur 32 adultes souffrant de goutte (diagnostiqués selon les critères de classification de la goutte ACR-EULAR) au service de consultations externes de l'hôpital 'Calcutta Homoeopathic Medical College and Hospital' à Kolkata. Les changements dans le taux d'acide urique sérique étaient le principal résultat (au départ par rapport à après 3 mois) ; le questionnaire 'Gout Assessment Questionnaire v2.0' (GAQ 2 -Questionnaire d'évaluation de la goutte ; au départ par rapport à après 3 mois) et le 'Measure Yourself Medical Outcome Profile v2.0' (MYMOP2 -Profil après l'auto-évaluation des résultats médicaux) ; au départ, chaque mois, jusqu'à 3 mois) étaient les résultats secondaires. L'échantillon 'intention de traiter' (n = 32) a été analysé dans SPSS ® IBM ® v.20. Résultats : L'âge moyen des patients était de 47,6 ans; le ratio hommes/femmes était de 5:3. Le taux d'acide urique sérique (mg/dl) chez les deux [7,6 ± 1,4 contre 6,0 ± 1,5 ; réduction moyenne 1,6, 95 % CI 1.1, 2,1, P<0,001, Test t de Student] et le score GAQ 2 total [45,0 ± 9,1 contre 21,0 ± 14,0 ; réduction moyenne : 24,0, 95 % CI 19,1, 29,0, P<0,001, test t de Student] ont baissé de manière sensible sur la période de 3 mois. Les scores MYMOP2 obtenus longitudinalement à 4 moments différents ont également révélé des réductions statistiquement significatives (P<0,001, mesure répétée à sens unique ANOVA). Le médicament le plus souvent prescrit était le Benzoicum acidum. Conclusion : Cette étude a révélé un effet thérapeutique prometteur de médicaments homéopathiques personnalisés pour soulager les symptômes de la goutte et améliorer la qualité de vie.
